Abstract
Pseudomonas aeruginosa is a highly successful opportunistic pathogen that displays intrinsic multidrug resistance and has a tremendous capacity to acquire further resistance mechanisms. During chronic infection, the bacterium can form a protective biofilm therefore reducing the efficacy of existing antibiotics. P. aeruginosa also harbors an impressive range of virulence factors, many of which are controlled by the quorum-sensing system. Several novel therapeutics are under investigation such as those directed against biofilm formation and quorum-sensing systems along with bacteriophages and immunotherapies. Recent advances in next-generation sequencing and comparative genomics have opened the door to a new wave of smart drug design that could revolutionize P. aeruginosa treatment options.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Adhesion / drug effects
-
Bacteriocins / administration & dosage
-
Bacteriocins / therapeutic use
-
Biofilms / drug effects
-
Biofilms / growth & development
-
Drug Resistance, Multiple, Bacterial
-
Humans
-
Immunotherapy
-
Iron Chelating Agents / administration & dosage
-
Iron Chelating Agents / therapeutic use
-
Plant Extracts / administration & dosage
-
Plant Extracts / therapeutic use
-
Pseudomonas Infections / immunology
-
Pseudomonas Infections / microbiology
-
Pseudomonas Infections / therapy*
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / genetics
-
Quorum Sensing / drug effects*
-
Quorum Sensing / genetics
-
Virulence / drug effects
-
Virulence / genetics
Substances
-
Anti-Bacterial Agents
-
Bacteriocins
-
Iron Chelating Agents
-
Plant Extracts